Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Nordic Nanovector
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, Nordic Nanovector gains access to highly promising new technology that enables the development and production of radionuclides for radioimmunoconjugate-based approaches to cancer treatment.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Nordic Nanovector
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Zentiva
Deal Size : Undisclosed
Deal Type : Acquisition
Zentiva Completes Major Product Acquisition from Tillomed Spain
Details : Through this acquisition, Zentiva will significantly increase its position in the Hospital sector and more specifically in the Oncology area with some value-added 16 products complementing the products recently launched.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 16, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Zentiva
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Moderna Exercises Option To License Proprietary Targeting Technology From Autolus
Details : This follows an original agreement with Moderna, granting Moderna an exclusive option to license Autolus’ proprietary binders for up to four immuno-oncology targets for incorporation in certain mRNA therapeutics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : University of Pennsylvania
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to enhance the understanding of CAR-T therapies using super-resolution microscopy, identifying predictive biomarkers and characteristics related to CAR-T treatment efficacy and safety, with the goal of improving patient outcomes.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : University of Pennsylvania
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Autolus will receive payment for access to the RQR8 safety switch for the initial set of cell therapy programs with the potential for near term option exercise fees and development milestone payments.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Oncorus
Deal Size : $7.7 million
Deal Type : Licensing Agreement
Details : Under the licensing agreement with Gaeta Therapeutics, Oncorus will advance ONCR-177 as a potential new therapeutic option for cancer patients, including in combination with pembrolizumab and locally delivered Interleukin-12 (IL-12) via oncolytic viral e...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $0.2 million
November 11, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Oncorus
Deal Size : $7.7 million
Deal Type : Licensing Agreement
Lead Product(s) : Daratumumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Type of Treatment Could Reawaken Immune Response Against Prostate Cancer
Details : Study suggests that therapies which target CD38-such as the multiple myeloma drug daratumumab-could hold promise against prostate cancer too, by reawakening the anti-cancer immune response.
Product Name : Darzalex
Product Type : Antibody
Upfront Cash : Inapplicable
July 05, 2021
Lead Product(s) : Daratumumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Ideaya Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration
Details : The expanded research collaboration will evaluate IDEAYA's PARG inhibitors in vitro in multiple ovarian cancer cell lines and in vivo in ovarian cancer xenograft models.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 03, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Ideaya Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed,Ipilimumab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Cancer Research
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration is based on clinical studies conducted by CUH that evaluate immune checkpoint inhibitor drug response in cancer patients, combined with Microbiotica’s unrivalled microbiome profiling and analysis capability.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 06, 2020
Lead Product(s) : Undisclosed,Ipilimumab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Cancer Research
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Foralumab,Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tiziana has submitted a patent application on potential use of Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), to improve success of CAR-T therapy for cancer and other human diseases.
Product Name : TZLS-401
Product Type : Antibody
Upfront Cash : Inapplicable
July 16, 2020
Lead Product(s) : Foralumab,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable